novo oral semaglutide US FDA accepts Nordisk's application for Wegovy for weight loss Novo Nordisk announced headline results

The trial is testing whether that benefit exists the answer is not yet known

Imbalances in BA influence disease progression through multiple mechanisms (1): modulating hepatic urate production via PPAR-/XOD signaling (2), regulating immune responses through FXR/TGR5-dependent suppression of NLRP3 inflammasome activation, and (3) shaping the gut microbiota composition, which reciprocally affects uric acid homeostasis and inflammation

Fuentes JP, Bezdicek DF, Flury M, Albrecht S, Smith JL

Personalized nutrition and exercise planning in conjunction with the medication regimen (since medication + lifestyle = best outcome)

J Adv Res 13:101112